TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31529059

Group type: EXPERIMENTAL
Intervention: 250 μg Synacthen
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1 mg dexamethasone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 42
Study: 31827470

Group type: EXPERIMENTAL
Intervention: IL‐15 pretreatment of NK effector cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27879993

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Number of subjects: 534

Group type: COMPARATOR
Intervention: Povidone-iodine
Number of subjects: 534
Study: 25055766

Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy (DOT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Self-Administered Therapy (SAT)
Number of subjects: 43
Study: 23768797

Group type: EXPERIMENTAL
Intervention: BodiMojo intervention for four weekly health class periods
Number of subjects: 178

Group type: COMPARATOR
Intervention: Usual health curriculum
Number of subjects: 178
Study: 21683991

Group type: EXPERIMENTAL
Intervention: Escherichia coli HU2117
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sterile saline (placebo)
Number of subjects: 65
Study: 19333693

Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral cataract surgery
Number of subjects: 194

Group type: COMPARATOR
Intervention: Separate bilateral cataract surgery
Number of subjects: 194
Study: 16493559

Group type: EXPERIMENTAL
Intervention: Test CVC complete set
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Guide wire ECG position control
Number of subjects: 76

Group type: COMPARATOR
Intervention: Fluid column ECG position control
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Adhesive fixation
Number of subjects: 76
Study: 15315844

Group type: EXPERIMENTAL
Intervention: Modified WHO regimen (Rifampicin 600 mg once a month supervised, 50 mg of Clofazimine and 100 mg of Dapsone daily unsupervised) and BCG 0.1 mg per dose 6 monthly
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Multi-drug treatment (MDT) and Mw (2 x 10(8) killed bacilli per dose) 6 monthly
Number of subjects: 36

Group type: COMPARATOR
Intervention: Multi-drug treatment (MDT) with 0.1 ml of distilled water 6 monthly (control group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both immunotherapy groups (groups I and II)
Number of subjects: 36

Group type: COMPARATOR
Intervention: MDT alone (control group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Immunotherapy groups (groups I and II)
Number of subjects: 36
Study: 11245341

Group type: EXPERIMENTAL
Intervention: Letter directing to visit primary care physician
Number of subjects: 1717

Group type: EXPERIMENTAL
Intervention: Letter directing to contact clinic directly to schedule a mammogram
Number of subjects: 1717

Group type: COMPARATOR
Intervention: No letter
Number of subjects: 1717
Study: 9093231

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8040775

Group type: EXPERIMENTAL
Intervention: Vancomycin (25 micrograms/ml)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control (no vancomycin)
Number of subjects: 141
Study: 2647033

Group type: EXPERIMENTAL
Intervention: Cotazym‐S‐Forte (10,000 BP units of lipase activity per capsule)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pancrease (5000 BP units of lipase activity per capsule)
Number of subjects: 0
Study: 31886280

Group type: EXPERIMENTAL
Intervention: Peer support education model
Number of subjects: 120

Group type: COMPARATOR
Intervention: Medical staff education model
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison between both groups
Number of subjects: 120
Study: 26514001

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 110

Group type: COMPARATOR
Intervention: Xuanfeijiedu granules
Number of subjects: 110
Study: 23829024

Group type: EXPERIMENTAL
Intervention: High flight workload with poor communication signal quality
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Assistive communication technology
Number of subjects: 20

Group type: COMPARATOR
Intervention: Passive headsets
Number of subjects: 20
Study: 21072224

Group type: EXPERIMENTAL
Intervention: Active trachoma prevalence in The Gambia
Number of subjects: 8155

Group type: EXPERIMENTAL
Intervention: Active trachoma prevalence in Tanzania
Number of subjects: 8155

Group type: EXPERIMENTAL
Intervention: Amplicor positive prevalence in The Gambia
Number of subjects: 8155

Group type: EXPERIMENTAL
Intervention: Amplicor positive prevalence in Tanzania
Number of subjects: 8155

Group type: EXPERIMENTAL
Intervention: Risk factors for follicular trachoma (TF) in both countries
Number of subjects: 8155

Group type: EXPERIMENTAL
Intervention: Additional risk factors in Tanzania
Number of subjects: 8155

Group type: EXPERIMENTAL
Intervention: Risk factors for being Amplicor positive in Tanzania
Number of subjects: 8155

Group type: EXPERIMENTAL
Intervention: Risk factor for being Amplicor positive in The Gambia
Number of subjects: 8155
Study: 18372389

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 2.4 g/day for 2 years
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no EPA treatment)
Number of subjects: 41
Study: 16614398

Group type: EXPERIMENTAL
Intervention: EGG (640 mg/d additional dietary cholesterol and 600 microg lutein + zeaxanthin)
Number of subjects: 91

Group type: COMPARATOR
Intervention: SUB (0 mg/d cholesterol, 0 microg lutein + zeaxanthin)
Number of subjects: 91
Study: 14714357

Group type: EXPERIMENTAL
Intervention: Puerarin Injection (PI) 200 ml by intravenous dripping once a day, starting one week before operation.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Puerarin Injection (PI)
Number of subjects: 78
Study: 10810000

Group type: EXPERIMENTAL
Intervention: 6 weeks of oral antivitamin K therapy
Number of subjects: 790

Group type: COMPARATOR
Intervention: 6 months of oral antivitamin K therapy
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 790
Study: 8908224

Group type: COMPARATOR
Intervention: Morphine IW, saline IM
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Saline IW, saline IM
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Saline IW, morphine IM
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 60
Study: 1920184

Group type: EXPERIMENTAL
Intervention: five-week daily exercise training
Number of subjects: 119

Group type: COMPARATOR
Intervention: exercise training including six sessions of relaxation therapy
Number of subjects: 119
Study: 7119271

Group type: EXPERIMENTAL
Intervention: Colloid osmotic pressure measurement after major surgical interventions
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Colloid osmotic pressure measurement after preoperative hemodilution
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Colloid osmotic pressure measurement to avoid albumin administrations
Number of subjects: 55
Study: 31927200

Group type: EXPERIMENTAL
Intervention: HBCACR intervention (RehaComTM software)
Number of subjects: 36
Study: 31439093

Group type: EXPERIMENTAL
Intervention: Filtek Z350 XT with nylon brush and Spectra paste
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Filtek Z350 XT with nylon brush and Qartz paste
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Filtek Z350 XT with nylon brush and Nupro paste
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Various combinations of pastes and brushes
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 90
Study: 27299516

Group type: EXPERIMENTAL
Intervention: Systemic-behavioral treatment modules of the SELBST program
Number of subjects: 10
Study: 27581815

Group type: EXPERIMENTAL
Intervention: Intervention group (statin adherence intervention)
Number of subjects: 1906
Study: 23289958

Group type: EXPERIMENTAL
Intervention: CoQ10 200 mg d(‐1) for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22522761

Group type: EXPERIMENTAL
Intervention: Pretransplant donor-specific antibodies
Number of subjects: 94

Group type: COMPARATOR
Intervention: Non-donor-specific antibodies
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Posttransplant donor-specific antibodies
Number of subjects: 94
Study: 19176539

Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD)
Number of subjects: 14703

Group type: COMPARATOR
Intervention: No chronic obstructive pulmonary disease (COPD)
Number of subjects: 14703

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 14703
Study: 18000105

Group type: EXPERIMENTAL
Intervention: Activating a significant-other representation in transference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Significant-other representation activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participant's own ethnic identity activation
Number of subjects: 0
Study: 14679386

Group type: EXPERIMENTAL
Intervention: Alcohol cue exposure after a sip of alcohol
Number of subjects: 20
Study: 11842916

Group type: EXPERIMENTAL
Intervention: 320 mg Ginkgo biloba/Panax ginseng combination
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 640 mg Ginkgo biloba/Panax ginseng combination
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 960 mg Ginkgo biloba/Panax ginseng combination
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10023471

Group type: EXPERIMENTAL
Intervention: 0.4% oxybuprocaine (benoxinate)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.5% amethocaine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.5% proxymetacaine
Number of subjects: 14
Study: 7846134

Group type: EXPERIMENTAL
Intervention: Continuous-wave ultrasound at a dosage of 1.5 W/cm2 for 5 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (contralateral forearm with zero ultrasound output)
Number of subjects: 20
Study: 2689046

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carteolol (20 mg daily)
Number of subjects: 10
Study: 1174242

Group type: EXPERIMENTAL
Intervention: Peyote ingestion
Number of subjects: 57

Group type: COMPARATOR
Intervention: Huichol Indian controls
Number of subjects: 57

Group type: COMPARATOR
Intervention: Laboratory controls
Number of subjects: 57
Study: 31071137

Group type: EXPERIMENTAL
Intervention: Enhanced and prolonged Holter‐ECG monitoring
Number of subjects: 398

Group type: COMPARATOR
Intervention: Routine ECG monitoring
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 398
Study: 28645475

Group type: EXPERIMENTAL
Intervention: Melatonin (intravenous and intracoronary bolus)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 26369324

Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Number of subjects: 485
Study: 22236208

Group type: EXPERIMENTAL
Intervention: 4 weeks loading
Number of subjects: 104

Group type: COMPARATOR
Intervention: 12 weeks loading
Number of subjects: 104
Study: 21354977

Group type: EXPERIMENTAL
Intervention: ON stimulation (3 months)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ON stimulation (1 year after surgery)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cognitive assessment (1 year after surgery)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 6
Study: 19934631

Group type: EXPERIMENTAL
Intervention: Obese picture
Number of subjects: 49

Group type: COMPARATOR
Intervention: Normal-weight picture
Number of subjects: 49
Study: 16971295

Group type: EXPERIMENTAL
Intervention: Supportive Therapy for Adherence to Antiretroviral Treatment (STAART)
Number of subjects: 63
Study: 12777339

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10675711

Group type: EXPERIMENTAL
Intervention: 99mTc‐labelled lactose carrier systems
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lactose carriers
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Budesonide redispersion
Number of subjects: 10
Study: 9583653

Group type: EXPERIMENTAL
Intervention: Intervention communities (CME training for physicians and staff)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Comparison communities
Number of subjects: 660
Study: 8450129

Group type: EXPERIMENTAL
Intervention: Individual health education
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Group health education
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Health education sessions (third group)
Number of subjects: 3
Study: 3551522

Group type: EXPERIMENTAL
Intervention: Today contraceptive sponge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diaphragm
Number of subjects: 0
Study: 29343528

Group type: EXPERIMENTAL
Intervention: IVTA+VIT group
Number of subjects: 81

Group type: COMPARATOR
Intervention: VIT group
Number of subjects: 81
Study: 27249080

Group type: EXPERIMENTAL
Intervention: Doxazosin XL (4 mg/d to 16 mg/d over 12 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (matched capsules)
Number of subjects: 8
Study: 24504804

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) 250 mg/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Meloxicam 7.5 mg/day
Number of subjects: 70
Study: 22044976

Group type: EXPERIMENTAL
Intervention: Magnetically anchored camera (MAGS)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Laparoscopic camera (LAP)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Flexible endoscope (ENDO)
Number of subjects: 4
Study: 20938880

Group type: EXPERIMENTAL
Intervention: FLEX Care®-enhanced routine psychosocial intervention
Number of subjects: 35

Group type: COMPARATOR
Intervention: Routine psychosocial intervention alone
Number of subjects: 35
Study: 18791356

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard anesthetic management (STD)
Number of subjects: 130
Study: 16129815

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 4528
Study: 12375378

Group type: EXPERIMENTAL
Intervention: Daily self-observation measure of parental disciplinary behavior (diary)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit technique (time-out)
Number of subjects: 0
Study: 10091825

Group type: EXPERIMENTAL
Intervention: Single-stage isoproterenol tilt table test
Number of subjects: 111

Group type: COMPARATOR
Intervention: Passive tilt table test
Number of subjects: 111
Study: 8672315

Group type: COMPARATOR
Intervention: Local anaesthetic alone (lignocaine 10 mg ml‐1 - bupivacaine 3.75 mg ml‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Local anaesthetic with adrenaline (5 micrograms ml‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Local anaesthetic with hyaluronidase (75 iu ml‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Local anaesthetic with adrenaline and hyaluronidase
Number of subjects: 24
Study: 2104079

Group type: EXPERIMENTAL
Intervention: Oral tobramycin
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 195920

Group type: EXPERIMENTAL
Intervention: Radiation treatment
Number of subjects: 359
Study: 31189519

Group type: EXPERIMENTAL
Intervention: IDegLira (insulin degludec plus liraglutide)
Number of subjects: 1012

Group type: COMPARATOR
Intervention: IGlar U100 (insulin glargine 100 units/mL)
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 1012
Study: 28332372

Group type: EXPERIMENTAL
Intervention: Aceclofenac controlled release (CR) 200 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aceclofenac 100 mg twice daily
Number of subjects: 100
Study: 24229795

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Waiting List Control (WLC)
Number of subjects: 57
Study: 23505167

Group type: EXPERIMENTAL
Intervention: 5‐h multimodal longitudinal obesity curriculum for residents based on the 5As
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 158
Study: 21609937

Group type: EXPERIMENTAL
Intervention: Capecitabine, oxaliplatin, and lapatinib
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study: 19890073

Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS) 3 mg/24 h
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS) 6 mg/24 h
Number of subjects: 62

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combined STS groups
Number of subjects: 62
Study: 16750667

Group type: EXPERIMENTAL
Intervention: MLPA (SALSA P036, P019, and P020 human telomere test kits)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: MLPA (2 kits)
Number of subjects: 95

Group type: COMPARATOR
Intervention: FISH
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: MLPA (1 probe)
Number of subjects: 95
Study: 15542048

Group type: COMPARATOR
Intervention: Oral estradiol treatment (1 mg 17-beta-estradiol + 1 mg drosperinone or 2 mg drosperinone or 3 mg drosperinone)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Transdermal estradiol treatment (45 microg 17-beta-estradiol + 30 microg levonorgestrel or 40 microg levonorgestrel)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Oral estradiol treatment
Number of subjects: 171

Group type: COMPARATOR
Intervention: Transdermal estradiol treatment
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Oral and transdermal estradiol therapy
Number of subjects: 171
Study: 16136910

Group type: EXPERIMENTAL
Intervention: Controlling measures including well-ventilation, washing clothes and bedclothes, catching dust frequently, exposing clothing or bedclothes in the sun
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Controlling measures
Number of subjects: 43

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 43
Study: 9308743

Group type: EXPERIMENTAL
Intervention: Napsagatran 5 mg/h
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Napsagatran 9 mg/h
Number of subjects: 110

Group type: COMPARATOR
Intervention: Unfractionated heparin (control)
Number of subjects: 110
Study: 8315426

Group type: COMPARATOR
Intervention: Continuous bladder irrigation with 200 mL/h of normal saline
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Continuous infusion mesna at 100% of the cyclophosphamide dose
Number of subjects: 200
Study: 3455568

Group type: EXPERIMENTAL
Intervention: Imotest
Number of subjects: 105

Group type: COMPARATOR
Intervention: Mantoux test (10 I.U.)
Number of subjects: 105
Study: 29679770

Group type: EXPERIMENTAL
Intervention: ETRIC form
Number of subjects: 198

Group type: COMPARATOR
Intervention: Standard consent form
Number of subjects: 198
Study: 27135916

Group type: EXPERIMENTAL
Intervention: Probiotic capsules (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, 2 × 10(9) CFU/g each) for 8 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Probiotic capsules
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (cellulose capsules) for 8 weeks
Number of subjects: 60
Study: 24964227

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (two group‐mediated workshop sessions based on social cognitive theory)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 141
Study: 22575038

Group type: EXPERIMENTAL
Intervention: Dietary weight loss intervention
Number of subjects: 123
Study: 21246850

Group type: EXPERIMENTAL
Intervention: Electric-moxibustion at Baihui (GV 20) for 20 and 30 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Electric-moxibustion at Shenque (CV 8) for 10, 20 and 30 minutes
Number of subjects: 20
Study: 18487781

Group type: EXPERIMENTAL
Intervention: Hybrid electronic-paper environment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Paper patient record
Number of subjects: 35
Study: 15915008

Group type: EXPERIMENTAL
Intervention: Formoterol HFA pMDI 24 microg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Formoterol HFA pMDI 12 microg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Formoterol DPI 24 microg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 12870693

Group type: EXPERIMENTAL
Intervention: Livestock-keeping group
Number of subjects: 426

Group type: COMPARATOR
Intervention: General population group
Number of subjects: 426
Study: 10588564

Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/mL, n = 73
Number of subjects: 144

Group type: COMPARATOR
Intervention: Bupivacaine 2.5 mg/mL, n = 71
Number of subjects: 144
Study: 8916473

Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Procainamide (therapeutic serum levels)
Number of subjects: 100
Study: 1908529

Group type: EXPERIMENTAL
Intervention: Netilmycin‐metronidazole
Number of subjects: 101

Group type: COMPARATOR
Intervention: Trimethoprim‐sulfamethoxazole
Number of subjects: 101
Study: 6685512

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate tape (1 piece, 40 mg/tape)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate tape (2-3 pieces, 40 mg/tape)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study: 31368588

Group type: EXPERIMENTAL
Intervention: Drug filling group (triamcinolone acetonide clotrimazole injected into the external auditory canal)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Drug smearing group (smearing antifungal cream once per day)
Number of subjects: 256
Study: 27836308

Group type: EXPERIMENTAL
Intervention: Multifactorial personalized intervention
Number of subjects: 155

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 155
Study: 26122923

Group type: EXPERIMENTAL
Intervention: Concept approach
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Ad hoc approach
Number of subjects: 142

Group type: COMPARATOR
Intervention: Comparison of both approaches
Number of subjects: 142
Study: 23905372

Group type: EXPERIMENTAL
Intervention: Pengyan Pill (PP) - 10 g each time, thrice daily for 14 consecutive days
Number of subjects: 188

Group type: COMPARATOR
Intervention: Azithromycin - 10 g each day for 7 consecutive days
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Pengyan Pill (PP)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 188